Results 61 to 70 of about 181,126 (162)

Programmed cell death-1 receptor mediated regulation of Tbet ⁺ NK1.1 ⁻ Innate Lymphoid Cells within the Tumor Microenvironment

, 2022
Lim JX, Lai CY, Mallett GE, McDonald D, Hulme G, Laba S, Shapanis A, Payne M, Patterson W, Alexander M, Coxhead J, Filby A, Plummer R, Lovat PE, Sciume G, Healy E, Amarnath S.   +16 more
europepmc   +1 more source

The Novel Role of the Expression of Toll-like Receptors TLR-5, TLR-6, and TLR-9 and Associated Up-Regulation of Programmed Cell Death 1 Receptor (PD-1) and Its Ligand (PD-L1) in Lung Sepsis. [PDF]

Int J Mol Sci
Sinos G, Schizas D, Kapelouzou A, Frountzas M, Katsimpoulas M, Mylonas KS, Kapetanakis EI, Papalampros A, Liakakos T, Alexandrou A.   +9 more
europepmc   +1 more source

Effect of CXCR5, PD-1 and ICOS on B-cell responses and relevance to myasthenia gravis. [PDF]

Clin Transl Immunology
Çebi M, Çakar A, Durmuş H, Parman Y, Saruhan-Direskeneli G.   +4 more
europepmc   +1 more source

Agitation, Alzheimer's disease, and autophagy: mechanistic insights into aging pathways, gut microbiome, and artificial intelligence. [PDF]

Front Immunol
Maiese K.
europepmc   +1 more source

Immunoexpression of programmed death receptor 1 and its ligands in oral cavity squamous cell carcinoma. [PDF]

Med Oral Patol Oral Cir Bucal
Anjos RS, Barros EF, Firmo AC, Nonaka CF, Carvalho MD, Godoy GP.   +5 more
europepmc   +1 more source

Immunogenic Cell Death: Unlocking New Frontiers in Cancer Immunotherapy. [PDF]

Cancer Innov
Yaacoub K.
europepmc   +1 more source

Localized bullous pemphigoid in a melanoma patient with dual exposure to PD-1 checkpoint inhibition and radiation therapy

JAAD Case Reports, 2017
Kelsey Hirotsu, MD, Albert S. Chiou, MD, Audris Chiang, BA, Jinah Kim, MD, PhD, Bernice Y. Kwong, MD, Silvina Pugliese, MD   +5 more
doaj   +1 more source

From M7824 to SHR-1701: lessons for dual PD-L1/TGF-β targeting. [PDF]

J Immunother Cancer
Yi M, Li T, Wu K, Dai Z.
europepmc   +1 more source

Emerging Roles of Regulated Cell Death-mediated Inflammation in Pathophysiology of Ocular Diseases. [PDF]

J Ophthalmic Vis Res
Sheibani N.
europepmc   +1 more source

Overcoming resistance to anti-PD-1/PD-L1 therapy in cancer. [PDF]

Cancer Drug Resist
Li L, Zhao Y, Shi X, Guo X, Zhang X, Li G, Meng Q, Zhang M, Yin M.   +8 more
europepmc   +1 more source